Peptidomics Platform Data: Medium-Molecular-Weight Compounds in Hyperlipidemia Plasma

A novel analytical platform based on capillary electrophoresis–high-resolution mass spectrometry (CE–HRMS) was developed for metabolomics of medium-molecular-weight compounds (MMWCs). The platform was applied to plasma samples from hyperlipidemia patients, identifying elevated levels of peptides like bradykinin, CLIP, schizophrenia-related peptides, 63 additional peptide fragments, and two unknown MMWCs. The dataset, created by Tomoaki Nitta and last updated on 2026-05-27, is shared under a CC-BY-NC-4.0 license on figshare.

Use Cases

• Discover novel peptide biomarkers based on the 63 protein-derived peptide fragments identified.
• Validate analytical sensitivity for low-abundance compounds based on the reported 10 pg/mL detection limit for peptides.
• Study metabolic dysregulation in hyperlipidemia based on the significantly elevated peptide levels found in patient plasma.
• Characterize medium-molecular-weight compounds (MMWCs) based on the platform's focus on molecules between 1000 and 10000 Da.

Strengths

• Platform sensitivity is quantified with a 60-fold increase in injection volume and detection limits of 10 pg/mL for specific peptides.
• Application to a specific clinical cohort is described, with findings of elevated peptides in hyperlipidemia patient plasma.
• The dataset includes findings on 63 identified peptide fragments and two unknown MMWCs.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 35.8 KB, indicating limited scope.

Provenance

Source

Tomoaki Nitta via figshare.

Collection Method

Data generated using a novel CE–HRMS platform with large-volume dual preconcentration by isotachophoresis and stacking (LDIS).

Freshness

Last updated 2026-05-27 08:05:03; freshness should be verified.